BOEU.F Stock Overview
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 29.23 |
| 52 Week High | SEK 31.70 |
| 52 Week Low | SEK 15.74 |
| Beta | 1.01 |
| 11 Month Change | 8.95% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 437.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOEU.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.8% | -4.0% | 0.6% |
| 1Y | n/a | 18.1% | 32.1% |
Return vs Industry: Insufficient data to determine how BOEU.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BOEU.F performed against the US Market.
Price Volatility
| BOEU.F volatility | |
|---|---|
| BOEU.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BOEU.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BOEU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 127 | Emil Billbäck | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| BOEU.F fundamental statistics | |
|---|---|
| Market cap | US$1.95b |
| Earnings (TTM) | US$28.58m |
| Revenue (TTM) | US$72.77m |
70.6x
P/E Ratio27.7x
P/S RatioIs BOEU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOEU.F income statement (TTM) | |
|---|---|
| Revenue | SEK 735.16m |
| Cost of Revenue | SEK 57.19m |
| Gross Profit | SEK 677.97m |
| Other Expenses | SEK 389.19m |
| Earnings | SEK 288.78m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 24, 2024
| Earnings per share (EPS) | 4.39 |
| Gross Margin | 92.22% |
| Net Profit Margin | 39.28% |
| Debt/Equity Ratio | 0% |
How did BOEU.F perform over the long term?
See historical performance and comparison